VaxGen, Inc. Announces Management Change; Senior Vice President, Research And Development And Chief Scientific Officer Resigns

BRISBANE, Calif., July 24 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN - News) today announced that Kathrin U. Jansen, Ph.D., the company's Senior Vice President, Research and Development and Chief Scientific Officer, has accepted the position of Senior Vice President of Vaccine Research at Wyeth (NYSE: WYE - News), and has resigned from VaxGen effective July 29, 2006. VaxGen has initiated a search for her replacement. Dr. Jansen joined VaxGen in October 2004 after having served as Executive Director of Microbial Vaccine Research for Merck Research Laboratories.

About VaxGen

VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox. The company has been awarded an $877.5 million contract by the U.S. Department of Health and Human Services to provide 75 million doses of a modern anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and owns a minority interest in Celltrion, Inc., a company in the Republic of Korea established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company's web site at: http://www.vaxgen.com.

Source: VaxGen, Inc.